Business context and reporting period
CNS Pharmaceuticals, Inc. filed this Form 8-K on October 1, 2026, reporting results of its annual stockholders’ meeting held September 30, 2026. The filing reports corporate-governance and equity-plan matters, not quarterly or annual financial results.
Key financial and capital information
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures. As of the August 10, 2026 record date, 1,461,449 common shares were issued and outstanding and entitled to vote. A quorum was present, with 668,188 shares (45.72%) represented.
Stockholders approved an amendment increasing the 2020 Equity Plan’s share authorization by 650,000 shares, to 765,061 shares in total. This is authorization under the plan; the filing does not state how many shares have been issued or remain available.
Material changes and meeting results
- Stockholders elected Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin, and Amy Mahery as directors until the 2027 annual meeting or until successors are qualified.
- Stockholders ratified MaloneBailey, LLP as the independent registered public accounting firm for the year ending December 31, 2026: 637,228 votes for, 30,874 against, and 89 abstentions.
- Stockholders approved, on an advisory basis, executive compensation: 98,103 votes for, 6,682 against, and 331 abstentions.
- Stockholders approved the 2020 Equity Plan amendment: 96,953 votes for, 8,128 against, and 35 abstentions.
- Stockholders authorized adjournment if needed to solicit additional proxies: 622,421 votes for, 45,635 against, and 132 abstentions.
Outlook, risks, and unusual items
The filing contains no financial guidance or operating outlook. The increased equity-plan authorization may enable additional share-based awards and potential dilution; the filing does not quantify expected grants or dilution. The complete amended plan is included as Exhibit 10.1.
Investor verification points
- Review Exhibit 10.1 and the August 21, 2026 proxy statement for plan terms, eligible awards, and share availability.
- Check subsequent filings for equity awards issued under the amended plan and their potential dilution.
- Consult the company’s financial filings for operating performance, cash runway, debt, and liquidity, which are not provided in this 8-K.